statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter...

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Pumas Board of Directors approved the grant of an inducement...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

For the last three days, A.I.dvisor has detected that PBYI's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Puma Biotechnology (PBYI, $5.31) Aroon Indicator entered a Downtrend on March 28, 2024.

Puma Biotechnology (PBYI, $5.59) Aroon Indicator entered a Downtrend on March 27, 2024.

In recent trading, shares of Puma Biotechnology Inc (PBYI) have crossed above the average analyst 12-month target price of 5.00, changing hands for 5.35/share. When a stock reaches the...

PBYI Crosses Above Average Analyst Target

Puma Biotechnology (PBYI, $5.35) Aroon Indicator entered a Downtrend on March 21, 2024.

Puma Biotechnology (PBYI, $4.69) Aroon Indicator entered a Downtrend on March 20, 2024.

This is a signal that PBYI's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Puma Biotechnology (PBYI, $4.69) RSI Indicator left the oversold zone on March 20, 2024

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application...

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Puma Biotechnology price target lowered by $1 at H.C. Wainwright, here's why

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Volume	77,437.00
52-Wk High	$7.73
52-Wk Low	$2.13

PBYI Puma Biotechnology Inc

About

Feed

News

Sentiment

Earnings

Fundamentals